| Novel Imaging Markers in SPMS (NCT05357833) | University of Utah | 2022-06-01 |
| Metformin Treatment in Progressive Multiple Sclerosis (NCT05349474) | University of California, Los Angeles | 2022-04-26 |
| Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis (NCT04925557) | State University of New York at Buffalo | 2021-11-13 |
| Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS (NCT05029609) | Tiziana Life Sciences LTD | 2021-10-01 |
| Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis (NCT04688788) | Rigshospitalet, Denmark | 2021-04-28 |
| Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) (NCT04792567) | Novartis Pharmaceuticals | 2021-04-19 |
| Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo (NCT05826028) | Novartis Pharmaceuticals | 2020-07-09 |
| SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis (NCT03783416) | Queen Mary University of London | 2020-06-15 |
| Acceptance Based Telephone Support When Transitioning to SPMS (NCT04239664) | University of Nottingham | 2019-09-09 |
| Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis (NCT06360861) | Tehran University of Medical Sciences | 2019-07-23 |
| Simvastatin in Secondary Progressive Multiple Sclerosis (NCT03896217) | University College, London | 2019-05-16 |
| Behavioural Activation for Low Mood in Multiple Sclerosis (NCT03935529) | University of Lincoln | 2019-03-04 |
| Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis (NCT03493841) | Rebecca Spain | 2018-06-08 |
| Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients (NCT03315923) | Isfahan University of Medical Sciences | 2017-12-01 |
| Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme (NCT03471338) | University Hospital, Caen | 2017-10-31 |
| Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis (NCT03283826) | Atara Biotherapeutics | 2017-10-19 |
| Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients (NCT03282760) | Casa Sollievo della Sofferenza IRCCS | 2017-09-09 |
| Mitochondrial Dysfunction and Disease Progression (NCT02549703) | Icahn School of Medicine at Mount Sinai | 2015-09-01 |
| Autologous Mesenchymal Stromal Cells for Multiple Sclerosis (NCT02495766) | Banc de Sang i Teixits | 2015-05-11 |
| MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (NCT01910259) | University College, London | 2014-12-18 |
| Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (NCT02330965) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-12-01 |
| A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (NCT02253264) | Johns Hopkins University | 2014-11-01 |
| Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis (NCT02266121) | University Hospital of Mont-Godinne | 2014-10-01 |
| Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (NCT02228213) | Innate Immunotherapeutics | 2014-10-01 |
| Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis (NCT02296346) | University of Utah | 2014-10-01 |
| Measuring Active Microglia in Progressive Multiple Sclerosis (NCT02207075) | Weill Medical College of Cornell University | 2014-07-01 |
| ACTH in Progressive Forms of MS (NCT01950234) | University of Minnesota | 2014-04-17 |
| A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS (NCT02208050) | University College Dublin | 2014-02-21 |
| A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (NCT01917019) | Biogen | 2013-08-01 |
| Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) (NCT01665144) | Novartis Pharmaceuticals | 2012-12-20 |
| A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis (NCT01737372) | John F. Foley, MD | 2012-11-01 |
| Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (NCT01684761) | Opexa Therapeutics, Inc. | 2012-08-01 |
| Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis (NCT01647321) | Johns Hopkins University | 2012-07-01 |
| Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition (NCT01466114) | University of California, Los Angeles | 2011-10-01 |
| A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (NCT01416181) | Biogen | 2011-09-13 |
| Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS (NCT00813969) | The Cleveland Clinic | 2011-03-01 |
| Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) (NCT01181089) | Biogen | 2010-09-01 |
| Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis (NCT01191996) | Innate Immunotherapeutics | 2010-08-01 |
| Natalizumab Treatment of Progressive Multiple Sclerosis (NCT01077466) | Rigshospitalet, Denmark | 2010-03-01 |
| Patient Research Cohort: Rapidly Evolving Multiple Sclerosis (NCT01044576) | Imperial College London | 2010-01-01 |
| AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis (NCT01228396) | Daval International Limited | 2009-05-01 |
| Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis (NCT00647348) | Imperial College London | 2008-01-01 |
| Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) (NCT00559702) | Biogen | 2007-10-01 |
| A Study for Patients With Multiple Sclerosis (NCT00870155) | Eli Lilly and Company | 2007-02-01 |
| A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis (NCT00257855) | University College London Hospitals | 2005-11-01 |
| Study Evaluating Mitoxantrone in Multiple Sclerosis (NCT00146159) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-03-01 |
| A Study for Patients With Secondary Progressive Multiple Sclerosis (NCT00869726) | Eli Lilly and Company | 2004-12-01 |